<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>It has recently been demonstrated that patients with <z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman's syndrome</z:e> who exhibited a deletion on cytogenetic tests show more severe clinical pictures with drug-resistant <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> than patients with <z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman's syndrome</z:e> not carrying the deletion </plain></SENT>
<SENT sid="1" pm="."><plain>To verify if this difference in clinical severity can be attributed to genes for the three <z:chebi fb="0" ids="16865">gamma-aminobutyric acid</z:chebi> (<z:chebi fb="3" ids="16865">GABA</z:chebi>)A receptor subunits (GABRB3, GABRA5, GABRG3) located in the deleted region, a possible modification of peripheral markers of the GABAergic system was investigated in 12 subjects with <z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman's syndrome</z:e> and 20 age-matched subjects (8 with <z:e sem="disease" ids="C0391957" disease_type="Disease or Syndrome" abbrv="">idiopathic epilepsy</z:e> and 12 not affected by <z:e sem="disease" ids="C1456669" disease_type="Disease or Syndrome" abbrv="">neurologic diseases</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>The results confirmed a more severe clinical picture, and <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> syndrome in particular, in <z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman's syndrome</z:e> patients with deletions versus patients without deletions </plain></SENT>
<SENT sid="3" pm="."><plain>In contrast, biochemical study (based on dosage of plasma levels of <z:chebi fb="3" ids="16865">GABA</z:chebi> and <z:chebi fb="11" ids="49575">diazepam</z:chebi> binding inhibitor, an endogenous ligand of GABAA and peripheral <z:chebi fb="13" ids="22720">benzodiazepine</z:chebi> receptors, showed contradictory results: patients with <z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman's syndrome</z:e> showed significantly higher levels of <z:chebi fb="3" ids="16865">GABA</z:chebi> and <z:chebi fb="11" ids="49575">diazepam</z:chebi> binding inhibitor than patients without neurologic impairment but significantly lower levels than <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epileptic</z:e> controls </plain></SENT>
</text></document>